What are the risks and recommended guidelines for using baclofen during pregnancy?

Baclofen in Pregnancy: Risks and Recommendations

Baclofen should be avoided during pregnancy whenever possible, but if clinically necessary for severe spasticity, use the lowest effective dose with gradual discontinuation before delivery to prevent neonatal withdrawal symptoms.

Critical Safety Concerns

The FDA drug label explicitly warns that baclofen causes neonatal withdrawal symptoms starting hours to days after delivery in infants whose mothers received the drug throughout pregnancy, manifesting as increased muscle tone, tremor, jitteriness, and seizures 1. This represents the most significant immediate risk to the newborn.

Teratogenic Risk Profile

Animal studies demonstrate concerning findings:

• Increased omphaloceles (ventral hernias) in rat fetuses at 13 times the maximum human dose
• Incomplete sternebral ossification in rats
• Unossified phalangeal nuclei in rabbits at 7 times human dose
• Reduced fetal weight and delayed skeletal ossification in mice 1

Human data from a comparative study of 134 pregnant women showed an increased risk of major malformations compared to 400 controls 2. However, the evidence quality is limited and requires cautious interpretation.

Clinical Management Algorithm

If Baclofen is Essential:

1. Dose Optimization

   • Use the absolute lowest effective dose
   • Monitor closely as pregnancy may require dose adjustments (pharmacokinetic changes can necessitate increases) 3
   • Document clear maternal benefit that outweighs fetal risk

2. Pre-Delivery Planning

   • Gradually taper and discontinue before delivery if medically feasible 1
   • If abrupt withdrawal poses maternal risk (hallucinations, seizures), maintain therapy but prepare neonatal team
   • Coordinate with neonatology for delivery planning

3. Neonatal Monitoring

   • Alert pediatric team to intrauterine baclofen exposure
   • Monitor newborn for withdrawal symptoms: extensor posturing, tremor, jitteriness, seizures 4
   • Consider Finnegan Neonatal Abstinence Scale for symptom tracking 4
   • Baclofen half-life in neonates is 3-fold longer than adults (approximately 10 hours) 5

Route-Specific Considerations

Intrathecal baclofen pumps appear to pose lower risk than oral administration due to minimal systemic exposure. Case reports show:

• Very low breast milk concentrations (0.617 ng/ml) 6
• Successful pregnancies with normal deliveries 3, 6
• May require dose increases during pregnancy for symptom control 3

Alternative Management Strategies

Before continuing baclofen, exhaust safer alternatives for spasticity management:

• Physical therapy and positioning
• Non-pharmacologic interventions
• If pharmacotherapy essential, discuss risk-benefit with maternal-fetal medicine specialist

Common Pitfalls to Avoid

1. Do not abruptly discontinue without tapering—maternal withdrawal causes hallucinations and seizures 1
2. Do not assume intrathecal = oral risk—intrathecal delivery has substantially different safety profile 6
3. Do not fail to warn parents about potential neonatal withdrawal if continuation necessary 1
4. Do not overlook renal function—baclofen is renally excreted; pregnancy-related renal changes affect clearance 1

Breastfeeding

Limited data suggest very low baclofen concentrations in breast milk with intrathecal administration 6. For oral baclofen, exercise caution and monitor infant for sedation or hypotonia. The risk-benefit assessment should consider maternal spasticity control needs versus potential infant exposure.

Documentation Requirements

When prescribing baclofen during pregnancy, document:

• Specific indication and severity of spasticity
• Failed alternative treatments
• Discussion of teratogenic and withdrawal risks
• Plan for pre-delivery tapering or neonatal monitoring
• Coordination with obstetrics and neonatology teams

The fundamental principle remains: maternal benefit must clearly justify fetal risk 1, and this threshold is high given the documented teratogenic potential and neonatal withdrawal syndrome.